

## **EVEREST ORGANICS LIMITED**

CIN: L24230TG1993PLC015426
An ISO 9001:2015 & WHO GMP Certified Company

Corporate Office: # 1st Floor, Lakeview Plaza, Plot No.127 & 128, Amar Co-operative Society, Opp. Madhapur Police Station Road, Near Durgam Cheruvu, Madhapur, Hyderabad - 500 033.

Tel: 040-40040783

Dated: 27.12.2019

EOL/SEC/COMP/060/2019-20

To, Bombay Stock Exchange, P.J. Towers, Dalal Street, Mumbai – 400001, Maharashtra, India

Dear Sir/ Ma'am.

Sub: Submission of Disclosure under Regulation 29 (2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Regulation 7 (2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015:

With reference to the captioned subject, please find enclosed herewith the disclosure received from the acquirer M/s. BK Advance Research, LLP, Person Acting in Concert (PAC) wherein one of the Partner in LLP is a Promoter of the Company, in Form 29(2) under Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Form C under Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Kindly take the above information on record.

Thanking You,

For Everest Organics Limited

Rekha Singh Company Secretary

Encl: As above

abad\*



## DR. SRIHARI RAJU SRIKAKARLAPUDI

R/o. Plot No. 127 & 128, 4<sup>th</sup> Floor, Amar Co-operative Society, Opp. Madhapur Police Station Road, Near Durgam Cheruvu, Madhapur, Hyderabad – 500033, Telangana Mobile No. 9440061672; Email ID: <a href="mailto:drsksraju@gmail.com">drsksraju@gmail.com</a>

Dated: 27.12.2019

To,

Bombay Stock Exchange, P.J. Towers, Dalal Street, Mumbai – 400001, Maharashtra, India The Compliance Officer, Everest Organics Limited, Aroor Village, Sadasivapet Mandal, Sangareddy (Medak) District, Telangana

Sub: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015:

Dear Sir/ Ma'am,

With reference to the captioned subject, please note that I, Dr. Srikakarlapudi Srihari Raju, designated partner of M/s. BK Advance Research, LLP, Person Acting in Concert as partner in LLP and being Promoter in Everest Organics Limited (hereinafter referred to as "the Company") is hereby submitting this disclosure for the intimation of acquisition of 500 Equity Shares representing 0.006% of the equity share capital of the Company through open market. In this regard, I hereby submit the disclosure required under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Regulation 7(2) read with regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Kindly take the above information on record.

Thanking You, Yours' Faithfully

Dr. Sri Kakarlapudi Srihari Raju Managing Director

DIN: 01593620

## Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	EVEREST OF	RGANICS LIMITE	D
Name(s) of the acquirer/transferor and Persons Acting in Concert (PAC) with the acquirer	BK ADVANCE	RESEARCH, LL	.P
Whether the acquirer belongs to Promoter/Promoter group	NO, Person A	cting in Concert	(PAC)
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BOMBAY ST	OCK EXCHANGE	
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC (*)
Before the acquisition/disposal under consideration, holding of:  a) Shares carrying voting rights b) Voting rights (VR) otherwise than by equity shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	19268	0.24%	NIL
d) Total (a+b+c)			
<ul> <li>Details of acquisition/sale</li> <li>a) Shares carrying voting rights acquired/sale/ Transfer</li> <li>b) VRs acquired otherwise than by equity shares</li> <li>c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)</li> </ul>	500	0.006%	NIL
acquired/sold			
d) Total (a+b+c)			
<ul><li>After the acquisition/sale, holding of:</li><li>a) Shares carrying voting rights</li><li>b) VRs otherwise than by equity shares</li></ul>	19768	0.246%	NIL




c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
d) Total (a+b+c)	19768	0.246%	NIL
Mode of acquisition/sale (e.g. open market / off-market / public issue / rights issue /preferential allotment / inter-se transfer etc.)	Open Marke		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	26-12-2019		
Equity share capital / total voting capital of the TC before the said acquisition/sale	Rs. 80,000,0 Shares of Rs		8000000 Equity
Equity share capital/ total voting capital of the TC after the said acquisition/sale	Rs. 80,000,0 Shares of Rs		8000000 Equity
Total diluted share/voting capital of the TC after the said acquisition/sale	Rs. 80,000,0 Shares of Rs		8000000 Equity

On Behalf of Acquirer

## SriK

Place: Hyderabad Date: 27.12.2019



40040783	040-	Contact No.:	500033	Hyderabad -	Madhapur,	Begumpet,	Guttala	S.Y.No. 47,	P.No. 127,	Address:	Office	Registered	LLPIN: AAN- 9113	AAUFB4409J	PAN:		LLP	Research,	Advance	Name: BK
																			(PAC)	Others
										ĺ									Shares	Equity
																			Shares (0.24%) Shares	19268
						ı													Shares	Equity
															,	ٔ	(0.006%	Shares	Equity	500
																			/-	85,378.28
							-													Buy
																			Shares	Equity
														П			,	ب	(0.246%	y 19768 26.12.
																			2019	26.12.
																			2019	26.12.
																				26.12. 27.12.2019
																			Market	Open

<sup>\*</sup>Note: "Securities" shall have the meaning as defined under regulation 2(1) (i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.



Details of Trading in derivatives of the Company by Promoter, Employee or Director of a listed company and other such persons as mentioned in Regulation 6(2).

	Types of Contract		15	•
Trading in d	Contract Specifications		16	
erivatives (Specif		Notional Value	17	i
Trading in derivatives (Specify type of contract, Futures or Options etc.)	Buy	Number of units (contracts*lot size)	18	•
tures or Options		Notional Value	19	4
etc.)	Sell	Number of units (contracts*lot size)	20	
Exchange on which the trade was executed			21	BSE Limited

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.

Signature:

Name: Dr. Sri Kakarlapudi Srihari ka

Date: 27.12.2019

Place: Hyderabad